SUPN vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 13, 2026

SUPN

42.2
AI Score
VS
PCRX Wins

PCRX

48.2
AI Score

Investment Advisor Scores

SUPN

42score
Recommendation
HOLD

PCRX

48score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric SUPN PCRX Winner
Revenue 426.76M 369.77M SUPN
Net Income -60.66M 7.57M PCRX
Net Margin -14.2% 2.0% PCRX
Operating Income -66.30M 11.17M PCRX
ROE -5.9% 1.1% PCRX
ROA -4.2% 0.6% PCRX
Total Assets 1.43B 1.24B SUPN
Cash 179.95M 205.88M PCRX
Current Ratio 2.08 5.04 PCRX
Free Cash Flow 61.15M 79.08M PCRX

Relative Price Performance (Last 90 Days)

SUPN 1M: -13.0% · 3M: -8.6% PCRX 1M: +7.0% · 3M: +8.6%

Current Technical Phase

SUPN

Markdown
Sell / avoid

Price below a falling SMA50 (slope -0.1%), weak momentum, RSI 31

RSI (14): 30.9 · Price: $41.64

PCRX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 49

RSI (14): 49.0 · Price: $25.36

Fundamentals Snapshot

Metric SUPN PCRX
Market Cap
Forward P/E 9.3 7.4
Trailing P/E 74.0
Revenue (TTM)
Revenue Growth 0.3% 0.1%
Gross Margin 0.7% 0.8%
Operating Margin 0.0% 0.1%
EPS -1.90 0.34
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.